The Effectiveness of Bleach in the Prevention of Hepatitis C Transmission - Final Report

References

1. Zou, S., Vardy, L. and Giulivi, A. Prevention and Control of Viral Hepatitis and Emerging Bloodborne Pathogens in Canada. Can Commun Dis Rep, 2001. 27 Suppl 3: p. 13-15.
2. Hepatitis C-prevent ion and control: a public health consensus. Ottawa, Canada, October 14-16, 1998. Can Commun Dis Rep, 1999. 25 Suppl 2: p. i-iii, 1-25.
3. Hepatitis. 2002, Health Canada. Ottawa, ON.
4. Hepatitis C & Injection Drug Use. 2001, Health Canada. Ottawa, ON.
5. Hepatitis C and Why is it a Problem? 2001, Health Canada. Ottawa, ON.
6. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep, 1998. 47(RR-19): p. 1-39.
7. Alter, M.J., et al., Hepatitis C. Infect Dis Clin North Am, 1998. 12(1): p. 13-26.
8. Page-Shafer, K.A., et al., Hepatitis C virus infection in young, low-income women: the role of sexually transmitted infection as a potential co-factor for HCV infection. Am J Public Health, 2002. 92(4): p. 670-6.
9. Bigham, M., Informed Decision-making about Mother-to-child Transmission of Hepatitis C Virus by Breastfeeding. 2000, BC Centre for Disease Control Society: Vancouver, BC.
10. Granovsky, M.O., et al., Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics, 1998. 102(2 Pt 1): p. 355-9.
11. Hepatitis C: medical information update. Canadian Liver Foundation. National Hepatitis C Education Program. Can J Public Health, 2000. 91 Suppl 1: p. S4-9.
12. Patrick, D.M., et al., Public health and hepatitis C. Can J Public Health, 2000. 91 Suppl 1: p.S18-21, S19-23.
13. Hepatitis C. Centers for Disease Control and Prevention. Hepatitis Branch. 2000: Atlanta, GA.
14. Weinstock, H.S., et al., Hepatitis C virus infection among patients attending a clinic for sexually transmitted diseases. JAMA, 1993. 269(3): p. 392-4.
15. Leonard, L., et al., The Effectiveness of Harm Reduction Strategies in Modifying Hepatitis C Infection among Injection Drug Users in Canada. Can Commun Dis Rep, 2001. 27 Suppl 3: p 52-55
16. Anderson, F.H., ed., N. Rock, ed., and S. Campbell, ed., The Hepatitis Knowledge Newsletter: Hep C: Transmission. n.d., HepNet: The Hepatitis Information Network.
17. Rose, V.L., CDC issues new recommendations for the prevention and control of hepatitis C virus infection. Am Fam Physician, 1999. 59(5): p. 1321-3.
18. Sattar, S.A., et al., Preventing the spread of hepatitis B and C viruses: where are germicides relevant? Am J Infect Control, 2001. 29(3): p. 187-97.
19. Sherman, M., The HepUpdate series: Update 1 - Fall 1995: How Significant is hepatitis C infection in Canada? 1995, HepNet: The Hepatitis Information Network.
20. Gully, P.R. and M.L. Tepper, Hepatitis C. CMAJ, 1997. 156(10): p. 1427-30.
21. Alter, M.J., et al., The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med, 1999. 341(8): p. 556-62.
22. Preventing the transmission of bloodborne pathogens in health care and public service settings. Can Commun Dis Rep, 1997. 23 Suppl 3: p. i-vii, 1-43, i-vii, 1-52.
23. Strathdee, S.A., et al., Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS, 1997. 11(8): p. F59-65.
24. Patrick, D.M., et al., Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ, 2001. 165(7): p. 889-95.
25. Ford, P.M., et al., Seroprevalence of hepatitis C in a Canadian federal penitentiary for women. Can Commun Dis Rep, 1995. 21(14): p. 132-4.
26. Pearson, M., P.S. Mistry, and P.M. Ford, Voluntary screening for hepatitis C in a Canadian federal penitentiary for men. Can Commun Dis Rep, 1995. 21(14): p. 134-6.
27. Roy, E., et al., Risk factors for hepatitis C virus infection among street youths. CMAJ, 2001. 165(5): p. 557-60.
28. Falck-Ytter, Y., et al., Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med, 2002. 136(4): p. 288-92.
29. Manns, M.P., et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001. 358(9286): p. 958-65.
30. Lauer, G.M. and B.D. Walker, Hepatitis C virus infection. N Engl J Med, 2001. 345(1): p. 41-52.
31. Sievert, W., Management issues in chronic viral hepatitis: hepatitis C. J Gastroenterol Hepatol, 2002. 17(4): p. 415-22.
32. Wiebe, J. and B. Reimer, Profile of Hepatitis C & Injection Drug Use in Canada. A Discussion Paper. Prepared for Hepatitis C Prevention, Support & Research Program. Population & Public Health Branch. Health Canada. 2000, Canadian Centre on Substance Abuse (CCSA): Ottawa, ON.
33. Preventing HIV Transmission: The Role of Sterile Needles and Bleach, ed. J. Normand, D. Vlahov, and L.E. Moses. 1995, Washington: National Academy Press.
34. Thorpe, L.E., et al., Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol, 2002. 155(7): p. 645-53.
35. Wood, E., et al., Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ, 2001. 165(4): p. 405-10.
36. Samuel, M.C., et al., Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect, 2001. 127(3): p. 475-84.
37. Kwiatkowski, C.F., K. Fortuin Corsi, and R.E. Booth, The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction, 2002. 97(10): p. 1289-94.
38. Jurgen, R. and D. Riley, Responding to AIDS and Drug Use in Prisons in Canada. 1997.
39. Kleinman, S., et al., The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev, 1997. 11(3): p. 155-72.
40. Fletcher, J. and D. Ciancone, Why life's a bleach (The Sodium Hypochlorite Story). Environmental Science & Engineering, 1996.
41. Newmeyer, J.A., Why bleach? Fighting AIDS contagion among intravenous drug users: the San Francisco experience. J Psychoactive Drugs, 1988. 20(2): p. 159-63.
42. Romanelli, F., K.M. Smith, and C. Pomeroy, Reducing the transmission of HIV-1: needle bleaching as a means of disinfection. J Am Pharm Assoc (Wash), 2000. 40(6): p. 812-7.
43. Ogborne, A.C., V. Carver, and J. Wiebe, Harm Reduction and Injection Drug Use: an international comparative study of contextual factors influencing the development and implementation of relevant policies and programs. 2001, Health Canada.
44. Rutala, W.A., et al., Stability and bactericidal activity of chlorine solutions. Infect Control Hosp Epidemiol, 1998. 19(5): p. 323-7.
45. Sehulster, L.M., et al., Immunological and biophysical alteration of hepatitis B virus antigens by sodium hypochlorite disinfection. Appl Environ Microbiol, 1981. 42(5): p. 762-7.
46. Carlson, R.G., et al., A preliminary evaluation of a modified needle-cleaning intervention using bleach among injection drug users. AIDS Educ Prev, 1998. 10(6): p. 523-32.
47. Hilfenhaus, J., et al., Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses. Transfusion, 1997. 37(9): p. 935-40.
48. Borovec, S., et al., Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat. Biologicals, 1998. 26(3): p. 237-44.
49. Shapshak, P., et al., Preliminary laboratory studies of inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. J Acquir Immune Defic Syndr, 1994. 7(7): p. 754-9.
50. Update on the Use of Bleach to Prevent Transmission of HIV and Hepatitis among Injection Drug Users. 1999, Public Health Seattle & King County.
51. Clarkson, R.M., A.J. Moule, and H.M. Podlich, The shelf-life of sodium hypochlorite irrigating solutions. Aust Dent J, 2001. 46(4): p. 269-76.
52. Kapadia, F., et al., Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users? Epidemiology, 2002. 13(6): p. 738-41.
53. Agolini, G., A. Russo, and M. Clementi, Effect of phenolic and chlorine disinfectants on hepatitis C virus binding and infectivity. Am J Infect Control, 1999. 27(3): p. 236-9.
54. Charrel, R.N., et al., Evaluation of disinfectant efficacy against hepatitis C virus using a RT-PCR-based method. J Hosp Infect, 2001. 49(2): p. 129-34.
55. Jamner, M.S., N.H. Corby, and R.J. Wolitski, Bleaching injection equipment: influencing factors among IDUs who share. Subst Use Misuse, 1996. 31(14): p. 1973-93.
56. Watters, J.K., Historical perspective on the use of bleach in HIV/AIDS prevention. J Acquir Immune Defic Syndr, 1994. 7(7): p. 743-6.
57. Use of bleach for disinfection of drug injection equipment. MMWR Morb Mortal Wkly Rep, 1993. 42(21): p. 418-9.
58. Knowledge and Practices Among Injecting-Drug Users of Bleach Use for Equipment Disinfection - New York city, 1993 . MMWR Morb Mortal Wkly Rep, 1994. 43(24): p. 445-446.
59. Haverkos, H.W. and T.S. Jones, HIV, drug-use paraphernalia, and bleach. J Acquir Immune Defic Syndr, 1994. 7(7): p. 741-2.
60. Rietmeijer, C.A., et al., Increasing the use of bleach and condoms among injecting drug users in Denver: outcomes of a targeted, community-level HIV prevention program. AIDS, 1996. 10(3): p. 291-8.
61. Hahn, J.A., et al., Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology, 2001. 34(1): p. 180-7.
62. Hong, Z., S. Zou, and A. Giulivi, Hepatitis B and its Control in Southeast Asia and China. Can Commun Dis Rep, 2001. 27 Suppl 3: p. 31-33.
63. Zhang, J., S. Zou, and A. Giulivi, Hepatitis B in Canada. Can Commun Dis Rep, 2001. 27 Suppl 3: p. 10-12.
64. Rutala, W.A., APIC guideline for selection and use of disinfectants. Am J Infect Control, 1990. 18(2): p. 99-117.
65. Bond, W.W., et al., Inactivation of hepatitis B virus by intermediate-to-high-level disinfectant chemicals. J Clin Microbiol, 1983. 18(3): p. 535-8.
66. Payan, C., et al., Inactivation of hepatitis B virus in plasma by hospital in-use chemical disinfectants assessed by a modified HepG2 cell culture. J Hosp Infect, 2001. 47(4): p. 282-7.
67. Thraenhart, O. and C. Jursch, Measures for Disinfection and Control of Viral Hepatitis, in Disinfection, Sterilization, and Preservation, S.S. Block, Editor. 2001, Lippincott Williams & Wilkins: Philadelphia. p. 585-615.
68. Gayle, H.D., J.F. O'Neill, and S.W. Gust, HIV Prevention Bulletin: Medical Advice for Persons Who Inject Illicit Drugs. 1997, Centers for Disease Control and Prevention. Divisions of HIV/AIDS Prevention. Altanta, GA.
69. HIV and AIDS in Canada: Surveillance Report to June 30, 2001. 2001, Health Canada: Ottawa, ON. p. 52.
70. Abdala, N., et al., Can HIV-1-contaminated syringes be disinfected? Implications for transmission among injection drug users. J Acquir Immune Defic Syndr, 2001. 28(5): p. 487-94.
71. Heimer, R., Syringe exchange programs: lowering the transmission of syringe-borne diseases and beyond. Public Health Rep, 1998. 113 Suppl 1: p. 67-74.
72. Titus, S., et al., Bleach use and HIV seroconversion among New York City injection drug users. J Acquir Immune Defic Syndr, 1994. 7(7): p. 700-4.
73. Riley, D., et al., Harm reduction: concepts and practice. A policy discussion paper. Subst Use Misuse, 1999. 34(1): p. 9-24.
74. Pollack, H.A., Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users. Med Decis Making, 2001. 21(5): p. 357-67.
75. Hagan, H., et al., Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health, 1995. 85(11): p. 1531-7.
76. Hurley, S.F., D.J. Jolley, and J.M. Kaldor, Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet, 1997. 349(9068): p. 1797-800.
77. Return on Investment in Needle & Syringe Programs in Australia. 2002, Commonwealth Department of Health and Ageing; Health Outcomes International Pty Ltd; National Centre for HIV Epidemiology and Clinical Research; Drummond, Michael: Canberra.
78. Des Jarlais, D.C., et al., HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet, 1996. 348(9033): p. 987-91.
79. Hagan, H., et al., Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol, 1999. 149(3): p. 203-13.
80. Bruneau, J., et al., High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol, 1997. 146(12): p. 994-1002.
81. Taylor, A., et al., Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? J Infect, 2000. 40(2): p. 176-83.
82. Mansson, A.S., et al., Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis, 2000. 32(3): p. 253-8.
83. Hutchinson, S.J., et al., Prevalence of hepatitis C among injectors in Scotland 1989-2000: declining trends among young injectors halt in the late 1990s. Epidemiol Infect, 2002. 128(3): p. 473-7.
84. Elliott, L., et al., The Winnipeg Injection Drug Epidemiology (W.I.D.E.) Study: A Study of the Epidemiology of Injection Drug Use and HIV Infection in Winnipeg, Manitoba. Final Report. 1999, Manitoba Health, Public Health and Epidemiology, Epidemiology Unit: Winnipeg.
85. Roy, E., et al., Drug injection among street youth: the first time. Addiction, 2002. 97(8): p. 1003-9.
86. Fry, C., S. Fox, and G. Rumbold, Establishing safe injecting rooms in Australia: attitudes of injecting drug users. Aust N Z J Public Health, 1999. 23(5): p. 501-4.
87. Kerr, T., Safe Injection Facilities: Proposal for a Vancouver Pilot Project. 2000, Harm Reduction Action Society: Vancouver.
88. Kent, H., Is Australia's safe injection site experiment bound for Vancouver? CMAJ, 2001. 164(9): p. 1332.
89. Kondro, W., Advocacy group urges safe injection facilities for Canada's addicts. Lancet, 2002. 359(9315): p. 1415.
90. Single, E. Harm Reduction as the basis for Hepatitis C policy and programming. in First Canadian Conference on Hepatitis C. 2001. Montreal: Canadian Centre on Substance Abuse.
91. Dolan, K.A., et al., Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. Drug and Alcohol Review, 2000. 19: p. 337-346.
92. van Beek, I. and S. Gilmour, Preference to have used a medically supervised injecting centre among injecting drug users in Kings Cross, Sydney. Aust N Z J Public Health, 2000. 24(5): p. 540-2.
93. Kaldor, J.M., et al., Six Month Process Report on the Medically Supervised Injecting Centre. 2001, University of New South Wales.
94. Obadia, Y., et al., Syringe vending machines for injection drug users: an experiment in Marseilles, France. Am J Public Health, 1999. 89(12): p. 1852-4.
95. Dodding, J. and M. Gaughwin, The syringe in the machine. Aust J Public Health, 1995. 19(4): p. 406-9.
96. Lawlor, E., et al., Transmission rates of hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation. Vox Sang, 1999. 76(3): p. 138-43.

[Previous] [Table of Contents]